12:00 AM
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Reminyl galantamine: Phase III

SHP and partner Janssen Pharmaceutica (Beerse, Belgium) said that patients treated with 16 and 24 mg/day of Reminyl had significantly better scores on cognitive, functional...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >